GlobeImmune has taken a big step forward in its second attempt to go public. Now the question is whether the Louisville, CO-based biotech will get to the finish line this time around. According to a regulatory filing posted by the company on Tuesday, GlobeImmune intends to price its shares between $15 and $17 apiece and sell 2,187,500 shares total at its IPO. GlobeImmune would pocket $32.8 million at $15 per share, and nearly $37.2 million if it reaches the $17 target.